VA Benefits: Trump Shares Update on Psychedelic Drug Treatment for Veterans

President Donald Trump on Tuesday reaffirmed his administration's push to expand access to psychedelic-assisted treatments for veterans suffering from post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and depression.

Key points

• The University of Miami's update to the 1994 ibogaine application could backing ongoing clinical research as the Trump administration continues its push to accelerate psychedelic medicine studies.
• According to Trump additionally, health and Human Services Secretary Robert F.
• Ibogaine is a naturally occurring psychoactive compound discovered in the root bark of the Tabernanthe iboga shrub native to Central Africa.
• Nevertheless, the drug remains a Schedule I controlled substance in the United States.
• "Psilocybin has been used for thousands of years and has a well-characterized safety profile, " Jared Ross, an emergency physician and professor at the University of Missouri, informed Newsweek.

Newsweek is a Trust Project member.

See more of our trusted coverage when you search.to see more of our trusted coverage when you search.

In a post on Truth Social, Trump confirmed a new step involving the hallucinogenic compound ibogaine.

"This is something that has helped so many of our amazing VETERANS and true American Heroes who were here in the Oval Office with me, and Joe Rogan, " Trump wrote. "Today I am announcing that Secretary Kennedy has received a Historic Gift from the University of Miami, who has given the Federal Government its original 1994 Ibogaine Investigational New Drug application."

For context, the Department of Veterans Affairs (VA) has expanded its research into psychedelic therapies, including clinical trials involving psilocybin aimed at veterans with treatment-resistant mental health conditions after an executive order in April from Trump to accelerate medical treatments for serious mental illness.

Mental health challenges are a major concern among the veteran community, and the Trump administration has increasingly focused on psychedelic therapies as a potential treatment option for veterans who have not responded to conventional medications or psychotherapy.

In April, Trump's executive order directed federal agencies to speed research and regulatory review of psychedelic-assisted therapies, including ibogaine, psilocybin, MDMA, ketamine and LSD. The order additionally called on roughly $50 million in federal backing for research initiatives and state-level programs studying psychedelic treatments for serious mental illness.

Veterans could be some of the mental health patients who benefit most if these treatments are ultimately proved safe and effective through clinical trials.

In his post on Truth Social, Trump remarked the University of Miami had provided the federal administration with its original 1994 investigational new drug (IND) application for ibogaine, a naturally occurring psychoactive compound derived from the African shrub Tabernanthe iboga.

According to Trump additionally, health and Human Services Secretary Robert F. Kennedy Jr. Had received the application. It will provide researchers and regulators with access to foundational Food and Drug Administration authorization materials related to ibogaine.

"We are moving FAST, so that our Veterans with serious mental illness have a RIGHT TO TRY here in the U.S., " Trump wrote. "We hope to see more firms and institutions join us in this highly significant work. Our Veterans DESERVE it!"

Experts say it may support treat PTSD, depression, addiction and other behavioral health disorders by promoting neuroplasticity and reducing withdrawal symptoms associated with substance apply disorders.

"The administration's willingness to embrace psychedelic medicine, particularly in the context of treating veterans, represents a historic shift in how America approaches mental health, " Jay Godfrey, CEO and co-founder of Nushama, informed Newsweek.

"For decades, veterans suffering from PTSD, depression, addiction and other treatment-resistant conditions have had far too few effective options. The emerging evidence for psychedelic therapies is extraordinarily promising, and the federal government's willingness to accelerate research and access could be transformative."

Nevertheless, the drug remains a Schedule I controlled substance in the United States. Federal regulators have not approved it for medical employ, and researchers have additionally triggered concern regarding potential cardiac risks associated with the treatment.

"This is much bigger than psychedelics. We are witnessing the beginning of a revolution in mental health and interventional psychiatry, " Godfrey remarked. "The question is no longer whether these therapies will become an important part of the mental-health landscape, but how quickly we can responsibly bring them to the millions of people who need them."

In practice, the new announcement arrives against the backdrop of broader efforts by the VA to examine psychedelic-assisted therapies.

Meanwhile, the department lately rolled out a clinical trial studying psilocybin, the psychoactive ingredient in "magic mushrooms, " for veterans with treatment-resistant depression and PTSD. The study is part of more than 20 psychedelic-related research efforts at present involving VA researchers.

In July, the VA and HHS additionally signed a memorandum of understanding designed to rise cooperation on psychedelic therapy research. The agencies remarked the agreement would expand clinical trial participation and collect further evidence on treatment outcomes.

"President Trump opened up a world of possibility for treating veterans and others with mental health conditions, and VA is proud to be part of this important work, " VA Secretary Doug Collins remarked at the time.

Interest in psychedelic treatments has grown over recent years as researchers search for alternatives for veterans whose conditions have not improved through existing treatments.

Some early studies have already shown promising results for conditions including PTSD, depression and addiction.

"Veterans need to understand that these treatments are not for everyone and they need careful screening, medical oversight, preparation, and follow-up, " Amber Capone, co-founder and CEO of Veterans Exploring Treatment Solutions, informed Newsweek. "But we've seen that veterans lack the luxury of waiting indefinitely, and moving the science forward responsibly could give more families real options sooner."

Still, experts caution that larger clinical trials are needed to establish the long-term safety and effectiveness. Ibogaine additionally carries unique health risks, particularly for residents with certain cardiovascular conditions.

"Psilocybin has been used for thousands of years and has a well-characterized safety profile, " Jared Ross, an emergency physician and professor at the University of Missouri, informed Newsweek. "While it does have some abuse potential, it is much lower than MDMA and doesn't carry the cardiac risks of ibogaine."

Notably, the University of Miami's update to the 1994 ibogaine application could backing ongoing clinical research as the Trump administration continues its push to accelerate psychedelic medicine studies.

"In the short run, the federal attention matters because it reduces stigma and encourages veterans to ask their providers about options they may not have known were legal, " Myriam Barthes, CEO and co-founder of Journey Clinical, informed Newsweek.

"In the long run, the question is not whether these medicines obtain approved. It is whether the healthcare system is ready to deliver them safely and affordably at scale."

For now, VA Benefits: Trump Shares Update on Psychedelic Drug Treatment for Veterans remains the part of the story worth watching, and further updates are likely as more details are confirmed.